ASCO 2021 | Future research in multiparametric imaging for prostate cancer diagnosis
Alistair Grey, FRCS (Urol), University College London, London, UK, discusses the direction of future research in multiparametric imaging for prostate cancer diagnosis following the CADMUS trial (ISRCTN38541912). CADMUS was a prospective paired cohort trial comparing multiparametric ultrasound (mpUSS) with multiparametric MRI (mpMRI) targeted biopsies in the detection of clinically significant prostate cancer. It was demonstrated that mpUSS has a diagnostic performance comparable to that of mpMRI and that significant cancer detection is improved using both scans. Dr Grey highlights the next steps in this investigation, including looking at the staging of scans for diagnosis, using machine learning for data interpretation, and standardizing post hoc reporting of mpUSS to improve the quality of results. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Alistair Grey, FRCS (Urol) has received travel and accommodation for training in the use of irreversible electroporation from Angiodynamics Ltd who manufacture the Nanoknife.
